Cardiovascular Safety of Nilotinib in Alzheimer Disease

Ann Neurol. 2021 Jan;89(1):196. doi: 10.1002/ana.25947. Epub 2020 Nov 7.

Authors

Sean Tan¹, Diva Baggio², Jake Shortt^{2

3}, Brian Ko^{1

4}

Affiliations

¹ MonashHeart, Monash Health, Clayton, Victoria, Australia.
² Monash Haematology, Monash Health, Clayton, Victoria, Australia.
³ School of Clinical Sciences at Monash Health, Faculty of Medicine Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
⁴ Monash Cardiovascular Research Centre, Monash University, Clayton, Victoria, Australia.

PMID: 33103269
DOI: 10.1002/ana.25947

No abstract available

Publication types

Letter
Comment

MeSH terms

Alzheimer Disease* / drug therapy
Biomarkers
Humans
Pyrimidines / adverse effects

Substances

Biomarkers
Pyrimidines
nilotinib